Belvedere Trading’s Tarsus Pharmaceuticals TARS Stock Holding History

Belvedere Trading’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,900	Closed	-$214K	–	900
2024 Q1	$214K	Buy	+5,900	New	+$173K	﹤0.01%	323

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Belvedere Trading's TARS Position: Q2 2024 in Review

Belvedere Trading sold out of Tarsus Pharmaceuticals (TARS) in Q2 2024, closing a stake of 4,709 shares — an estimated $171K sold.

Belvedere Trading first reported a position in TARS in Q1 2024 and held it in 1 quarter. The position peaked at $171K in Q1 2024. 148 funds tracked by Wall St. Rank hold TARS as of Q2 2024.

Belvedere Trading reported no remaining Tarsus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Belvedere Trading sold 4,709 Tarsus Pharmaceuticals shares in Q2 2024, an estimated $171K.
Belvedere Trading first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 1 quarter.
Belvedere Trading's Tarsus Pharmaceuticals position peaked at $171K in Q1 2024.
148 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.